Table 7.
Early clinical and radiological response (RECIST v.1.0) to RE using 188Re HSA microspheres in patients with advanced progressive primary and secondary liver cancers evaluated after 6 weeks, 3 months, and 6 months.
| Clinical No. of patients (%) |
RECIST v.1.0 No. of patients (%) |
|
|---|---|---|
| Early 6 weeks (N=13) | ||
| PR | 7 (54) | 0 |
| SD | 5 (38) | 12 (92) |
| DP | 1 (8) | 1 (8) |
| At 3 months (N=13) | ||
| PR | 5 (38) | 1 (8) |
| SD | 6 (46) | 7 (54) |
| DP | 2 (15) | 5 (38) |
| At 6 months (N=8) | ||
| PR | 2 (25) | 0 |
| SD | 4 (50) | 6 (75) |
| DP | 2 (25) | 2 (25) |
RECIST v.1.0. DP – disease progression; PR – partial response; N/A – not applicable; SD – stable disease.